Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Wednesday 03 June, 2020

Northern Trust Corp

Form 8.3 - Willis Towers Watson PLC

RNS Number : 8601O
Northern Trust Corporation
03 June 2020
 

Ap19

 

 

FORM   8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.  KEY   INFORMATION

 

Nameofpersondealing (Note 1)

 Northern Trust Corporation

Companydealtin

  Willis Towers Watson plc

Classofrelevantsecuritytowhichthe dealingsbeingdisclosedrelate (Note 2)

 Common Stock USD 0.01

Date of dealing

 2nd June 2020

 

 

2.  INTERESTS AND SHORT POSITIONS

 

(a)  Interests   and   short   positions   (following   dealing)   in   the   class   of   relevant   security   dealt   in   (Note   3)

 

Long

Short

 

Number

 

(%)

Number

 

(%)

(1)Relevantsecurities

 1,574,887  1.22%

 

(2) Derivatives (other than options)

 

 

 

(3)Optionsandagreementstopurchase/sell

 

 

Total

 1,574,887  1.22%

 

             

 

Note: The difference in holdings from yesterday and today not explained by transactions, can be explained by stock transfers of 368 securities out of the relevant accounts.

 

 

(b)  Interests and short positions in relevant securities of the company, other than the class dealt in  (Note   3)

Classofrelevantsecurity:

Long

Short

 

Number

 

(%)

Number

 

(%)

(1)Relevantsecurities

 

 

 

(2) Derivatives (other than options)

 

 

 

(3)Optionsandagreementstopurchase/sell

 

 

Total

 

 

             

 

Ap20

 

 

1.  DEALINGS  (Note   4)

 

(a)  Purchases and sales

 

 

Purchase/sale

 

Numberofrelevantsecurities

 

Priceperunit ($)

SELL

2

201.13

BUY

3

201.86

BUY

1

201.13

SELL

6

201.13

BUY

36

201.89

BUY

3

201.13

BUY

120

201.86

SELL

6

201.13

SELL

2

201.13

BUY

15

201.86

SELL

2

202.89

SELL

2

202.89

 

 

(b)  Derivatives transactions (other than options transactions)

 

Productname,

e.g. CFD

Natureoftransaction

(Note 6)

Numberofrelevantsecurities

(Note 7)

Priceperunit

(Note 5)

 

 

 

 

 

 

(c)  Options transactions in respect of existing relevant securities

 

 

(i)  Writing, selling, purchasing or varying

 

Productname,

e.g. call option

Writing, selling,purchasing,varyingetc.

Numberofsecurities towhichtheoptionrelates (Note 7)

Exercise price

Type, e.g.American,Europeanetc.

Expiry date

Optionmoney paid/receivedperunit (Note 5)

 

 

 

 

 

 

 

 

 

(ii)  Exercising

 

Productname,

e.g. call option

Numberofsecurities

Exercisepriceper unit (Note 5)

 

 

 

 

 

(d)  Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

 

 

   

 

2.  OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any
relevant securities to which any derivative referred to on this form is referenced. If none, this
should be stated.

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached?  (Note   9)    NO

 

Dateofdisclosure

 3rd June 2020

Contact name

 Trish McMenamin

Telephone number

 3535717287

If aconnectedEFM,nameofofferee/offerorwithwhichconnected

 

 

If aconnectedEFM,statenatureofconnection (Note 10)

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEFLFFVRTIVIII

a d v e r t i s e m e n t